Skip to main content

Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.

Publication ,  Other
Ghadimi, K; Dombrowski, KE; Levy, JH; Welsby, IJ
Published in: Expert Rev Hematol
2016

Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin:LMWH complex but does not trigger prothrombotic activity. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. Further trials are underway to examine its safety and efficacy in the population of patients experiencing FXa inhibitor-related bleeding.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Hematol

DOI

EISSN

1747-4094

Publication Date

2016

Volume

9

Issue

2

Start / End Page

115 / 122

Location

England

Related Subject Headings

  • Recombinant Proteins
  • Protein Binding
  • Humans
  • Factor Xa Inhibitors
  • Factor Xa
  • Drug Evaluation, Preclinical
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase I as Topic
  • Blood Coagulation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ghadimi, K., Dombrowski, K. E., Levy, J. H., & Welsby, I. J. (2016). Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol, 9(2), 115–122. https://doi.org/10.1586/17474086.2016.1135046
Ghadimi, Kamrouz, Keith E. Dombrowski, Jerrold H. Levy, and Ian J. Welsby. “Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.Expert Rev Hematol 9, no. 2 (2016): 115–22. https://doi.org/10.1586/17474086.2016.1135046.
Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol. 2016;9(2):115–22.
Ghadimi, Kamrouz, et al. “Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.Expert Rev Hematol, vol. 9, no. 2, 2016, pp. 115–22. Pubmed, doi:10.1586/17474086.2016.1135046.
Ghadimi K, Dombrowski KE, Levy JH, Welsby IJ. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Expert Rev Hematol. 2016;9(2):115–122.

Published In

Expert Rev Hematol

DOI

EISSN

1747-4094

Publication Date

2016

Volume

9

Issue

2

Start / End Page

115 / 122

Location

England

Related Subject Headings

  • Recombinant Proteins
  • Protein Binding
  • Humans
  • Factor Xa Inhibitors
  • Factor Xa
  • Drug Evaluation, Preclinical
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase I as Topic
  • Blood Coagulation